41P Progression after chemo-IO and durvalumab in stage III non-small cell lung cancer (NSCLC): What should be the next line? Real-world studyT. Shentzer Kutiel, S. Shamai, B. Waissengrin,D. Urban,S. Daher, H. Sorotzky, M. Wollner, A. Zer,J. Bar,M. MoskovitzAnnals of Oncology（2022）引用 1|浏览1暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
